Sickle Cell Disease Drug Market to Witness Astonishing Growth by 2029

The global sickle cell disease drug market is anticipated to grow at a considerable CAGR during the forecast period. The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in June 2020, Emmaus Medical Inc. has received approval from the Israeli Ministry of Health for the commercial distribution of Endari in Israel. Endari is an L-Glutamine oral powder that is used to treat acute complications of sickle cell disease in adults and children age 5 years and older. Further, in October 2020, Medunik USA Inc. launched Siklos for pediatric patients with sickle cell diseases. Siklos is a 100 mg film-coated tablet, that is used to reduce the painful crisis caused by sickle cell disease. According to Medunik USA Inc., skilos are anticipated to reduce the need for blood transfusions. Similarly, in October 2020, the European Commission (EC) has approved the Adakveo drug for commercialization.

Moreover, in October 2020, the US Food and Drug Administration has approved Rivipansel  (GMI-1070) for the treatment of sickle cell disease. Rivipansel is developed by GlycoMemitics in partnership with Pfizer. The revipansel is used to treat the pain crisis, sickle cell disease, and sickle cell-related disorders. Further in January 2022, Sangamo Therapeutics Inc. has developed SAR445136, a zinc finger nuclease gene-edited cell therapy. Sanofi will be transitioning its rights and obligation related to SAR445136. In November 2019, Novartis AG has launched Adkaveo. Adakveo (Crizanlizumab –tmca) is indicated to reduce the Vasco-occlusive crisis in adults and pediatric patients aged 16 years and older.

To Request a Sample of our Report on Sickle Cell Disease Drug Market:  https://www.omrglobal.com/request-sample/sickle-cell-disease-drug-market

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028

Segment Covered- 

  • By Treatment
  • By End-User

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape-   Novartis AG, Global Blood Therapeutics Inc., Medunik USA Inc., Bristol-Myers Squibb Co, Emmaus Medical Inc., and more

Sickle Cell Disease Drug Market Report Segment

By Treatment 

  • Blood Infusion Treatment
  • Bone Marrow Transplant
  • Pharmacotherapy

By End-User

  • Specialty clinic
  • Hospitals

A full Report of Sickle Cell Disease Drug Market is Available @  https://www.omrglobal.com/industry-reports/sickle-cell-disease-drug-market

Sickle Cell Disease Drug Market Report Segment by Region

North America                                                                                                                                                                            

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe

Asia-Pacific

  • India
  • China
  • Japan
  • South Korea
  • Rest of APAC

Rest of the World

  • Latin America
  • Middle East and Africa

Company Profiles 

  • Alnylam Pharmaceuticals, Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca Plc.
  • Acceleron Pharma, Inc.
  • Bluebird bio, Inc.
  • Baxter International, Inc.
  • Daiichi Sankyo Co.
  • Reddy’s Laboratories, Ltd.
  • Eli Lilly &Co.
  • Johnson & Johnson Services, Inc.
  • SANOFI
  • Sangamo Therapeutics, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Co., Ltd.

Reasons to buy from us –

  1. We cover more than 15 major industries, further segmented into more than 90 sectors.
  2. More than 120 countries are for analysis.
  3. Over 100+ paid data sources mined for investigation.
  4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/sickle-cell-disease-drug-market

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404